Healthcare / Medical Care FacilitiesBSE
$1301.30
+0.60 (+0.05%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 17%
FCF escenarios
weak_data · normalized FCF $-608.5M · quality 40.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
52/100
C
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$85.3B
P/E
44.1x
↑EV/EBITDA
23.8x
↑ROE
12.6%
↑Gross Margin
80.8%
↑Debt/Equity
0.38
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2023–2026 · 3 años de histórico normalizado
Revenue CAGR
+18.9%
FCF CAGR
—
FCF margin
-15.6%
FCF / Net income
-1.20x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $15.00B · net income $1.94B · FCF $-2.34B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2026 | 2025 | 2024 | 2023 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $15.00B | $15.00B | $13.02B | $10.70B | $8.93B |
| Net Income | $1.94B | $1.94B | $1.92B | $1.77B | $729.0M |
| EBITDA | $3.81B | $3.81B | $3.28B | $2.60B | $2.06B |
| EPS | — | — | 29.47 | 28.44 | 11.12 |
| Gross Margin | 80.8% | 80.8% | 80.4% | 80.0% | 79.7% |
| Operating Margin | 17.0% | 17.0% | 18.7% | 18.8% | 18.4% |
| Net Margin | 13.0% | 13.0% | 14.7% | 16.5% | 8.2% |
| Balance Sheet | |||||
| Debt/Equity | 0.38 | 0.38 | 0.29 | — | 1.28 |
| Current Ratio | 3.02 | 3.02 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-2.34B | $-2.34B | $-608.5M | $292.3M | $399.2M |
| Returns | |||||
| ROE | 12.6% | 12.6% | 14.2% | 15.1% | 19.9% |
| Valuation | |||||
| P/E | 44.08 | 44.08 | 52.87 | 42.54 | — |
| EV/EBITDA | 23.80 | 23.80 | 30.98 | 28.51 | — |
| P/B | 5.53 | 5.53 | 7.49 | 6.37 | — |
| Growth & Yield | |||||
| Revenue Growth | 15.2% | 15.2% | 21.8% | 19.8% | — |
| EPS Growth | — | — | 3.6% | 155.8% | — |
| Dividend Yield | 0.1% | 0.1% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-8.3%
Start / end P/E
n/dx → n/dx
EPS bridge
29.47 → n/d
Residual
-8.4%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.